Protagenic Therapeutics Inc (NASDAQ:PTIX)’s traded shares stood at 1.27 million during the last session. At the close of trading, the stock’s price was $6.14, to imply a decrease of -10.76% or -$0.74 in intraday trading. The PTIX share’s 52-week high remains $26.18, putting it -326.38% down since that peak but still an impressive 61.73% since price per share fell to its 52-week low of $2.35. The company has a valuation of $3.61M, with an average of 10.43 million shares in intraday trading volume over the past 10 days and average of 2.09 million shares over the past 3 months.

Protagenic Therapeutics Inc (NASDAQ:PTIX) trade information

After registering a -10.76% downside in the last session, Protagenic Therapeutics Inc (PTIX) has traded red over the past five days. The 5-day price performance for the stock is 87.20%, and 94.49% over 30 days. With these gigs, the year-to-date price performance is -10.50%. Short interest in Protagenic Therapeutics Inc (NASDAQ:PTIX) saw shorts transact 16929.0 shares and set a 0.02 days time to cover.

PTIX Dividends

Protagenic Therapeutics Inc has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Protagenic Therapeutics Inc (NASDAQ:PTIX)’s Major holders

Protagenic Therapeutics Inc insiders hold 16.53% of total outstanding shares, with institutional holders owning 7.01% of the shares at 8.40% float percentage. In total, 7.01% institutions holds shares in the company.

We also have Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Protagenic Therapeutics Inc (PTIX) shares. Going by data provided on Mar 31, 2025 , Fidelity Concord Street Trust-Fidelity Extended Market Index Fund holds roughly 3.27 shares. This is just over 0.56% of the total shares, with a market valuation of $20077.0. Data from the same date shows that the other fund manager holds a little less at 2.29, or 0.39% of the shares, all valued at about 14029.0.